Cobimetinib - 934660-93-2

Cobimetinib

Catalog Number: EVT-288162
CAS Number: 934660-93-2
Molecular Formula: C22H22F3IN2O2
Molecular Weight: 530.32196
The product is for non-human research only. Not for therapeutic or veterinary use.
Price:

Product Introduction

Description

Cobimetinib is a MEK inhibitor that has been extensively studied for its therapeutic potential in various cancers. It has been approved for the treatment of advanced melanoma with a BRAF V600 mutation and is being investigated for its efficacy in other malignancies. Cobimetinib works by targeting the mitogen-activated protein kinase (MAPK) pathway, which is often dysregulated in cancer. The drug has shown promise in improving progression-free survival and overall survival in patients with specific cancer types, and its combination with other treatments has been a focus of recent research13410.

Mechanism of Action

Cobimetinib selectively inhibits MEK1/2, which are critical components of the MAPK pathway. This pathway is involved in cell division and survival, and its dysregulation can lead to uncontrolled cell proliferation and cancer progression. By inhibiting MEK, cobimetinib disrupts the pathway, leading to reduced tumor cell growth and increased apoptosis. The drug's effectiveness is particularly notable in cancers with mutations in the BRAF gene, which is upstream of MEK in the MAPK pathway134.

Applications in Various Fields

Melanoma

Cobimetinib, in combination with vemurafenib, has been shown to improve progression-free survival and overall survival in patients with BRAF V600-mutant advanced melanoma. The coBRIM study demonstrated that this combination is a standard first-line approach to improve survival in these patients. The safety profile was considered tolerable and manageable, with no new safety signals observed with longer follow-up1.

Brain Penetration and Pharmacodynamics

The role of P-glycoprotein (P-gp) in the brain penetration and pharmacodynamic activity of cobimetinib has been studied. Cobimetinib is a substrate of P-gp but not of breast cancer resistance protein (Bcrp1). This efflux by P-gp may have implications for the treatment of patients with brain tumors or metastases, as it affects the drug's ability to penetrate the brain and exert its pharmacodynamic effects2.

Hepatocellular Carcinoma

Cobimetinib has shown efficacy against hepatocellular carcinoma (HCC) cells, including those resistant to sorafenib. It has been found to inhibit tumor angiogenesis and induce apoptosis in HCC cells. These findings support the potential use of cobimetinib in treating HCC and highlight the therapeutic value of inhibiting the MEK/ERK/RSK pathway to overcome resistance3.

Osteosarcoma

In osteosarcoma models, cobimetinib has been reported to enhance the efficacy of doxorubicin. It inhibits growth and survival of osteosarcoma cells and has anti-metastasis activity. The combination of cobimetinib and doxorubicin could be a useful addition to the treatment armamentarium for osteosarcoma4.

Combination with ERK Inhibitors

A Phase Ib study evaluated cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors. The study aimed to target multiple nodes in the MAPK pathway to enhance activity and reduce potential for acquired resistance. However, the combination faced challenges with tolerability and cumulative toxicity, which restricted further development5.

Triple-Negative Breast Cancer

The COLET study is a phase 2 study evaluating the safety and efficacy of cobimetinib in combination with paclitaxel as a first-line treatment for patients with metastatic triple-negative breast cancer (TNBC). The rationale is that up-regulation of the MAPK pathway could be a resistance mechanism against taxane chemotherapy, and MEK inhibition could be an effective treatment option6.

Pharmacokinetics and Metabolism

Cobimetinib's absorption, metabolism, and routes of excretion have been assessed, revealing that it is predominantly excreted in feces and extensively metabolized. Intestinal metabolism appears to contribute significantly to the oral clearance of cobimetinib7.

Combination with AKT Inhibitors

A Phase Ib study explored the combination of cobimetinib with the pan-AKT inhibitor ipatasertib in patients with advanced solid tumors. The combination showed limited tolerability and efficacy, but pharmacodynamic analyses indicated target engagement, suggesting a rationale for further exploration in combination with other anticancer agents8.

Colorectal Cancer

Cobimetinib has potential application in colorectal cancer therapy. It inhibits cell proliferation, induces G1 phase arrest, and apoptosis in colorectal cancer cells. The drug also affects genes associated with the cell cycle and apoptosis, suggesting its usefulness in colorectal cancer treatment9.

Treatment of Melanoma

Cobimetinib combined with vemurafenib is an approved MEK inhibitor for the first-line treatment of metastatic melanoma with BRAF V600 mutations. It has been shown to improve tumor response rates and progression-free survival compared to vemurafenib alone10.

Properties

CAS Number

934660-93-2

Product Name

Cobimetinib

IUPAC Name

[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone

Molecular Formula

C22H22F3IN2O2

Molecular Weight

530.32196

InChI

InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1

InChI Key

FIAWSLMDMMCNMU-HHCSFTFJSA-N

SMILES

C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O

Solubility

Soluble in DMSO, not in water

Synonyms

XL518; XL 518; XL-518; GDC0973; GDC 0973; GDC-0973; RG 7420; RG-7420; RG7420; cobimetinib; Cotellic.

Product FAQ

Q1: How Can I Obtain a Quote for a Product I'm Interested In?
  • To receive a quotation, send us an inquiry about the desired product.
  • The quote will cover pack size options, pricing, and availability details.
  • If applicable, estimated lead times for custom synthesis or sourcing will be provided.
  • Quotations are valid for 30 days, unless specified otherwise.
Q2: What Are the Payment Terms for Ordering Products?
  • New customers generally require full prepayment.
  • NET 30 payment terms can be arranged for customers with established credit.
  • Contact our customer service to set up a credit account for NET 30 terms.
  • We accept purchase orders (POs) from universities, research institutions, and government agencies.
Q3: Which Payment Methods Are Accepted?
  • Preferred methods include bank transfers (ACH/wire) and credit cards.
  • Request a proforma invoice for bank transfer details.
  • For credit card payments, ask sales representatives for a secure payment link.
  • Checks aren't accepted as prepayment, but they can be used for post-payment on NET 30 orders.
Q4: How Do I Place and Confirm an Order?
  • Orders are confirmed upon receiving official order requests.
  • Provide full prepayment or submit purchase orders for credit account customers.
  • Send purchase orders to sales@EVITACHEM.com.
  • A confirmation email with estimated shipping date follows processing.
Q5: What's the Shipping and Delivery Process Like?
  • Our standard shipping partner is FedEx (Standard Overnight, 2Day, FedEx International Priority), unless otherwise agreed.
  • You can use your FedEx account; specify this on the purchase order or inform customer service.
  • Customers are responsible for customs duties and taxes on international shipments.
Q6: How Can I Get Assistance During the Ordering Process?
  • Reach out to our customer service representatives at sales@EVITACHEM.com.
  • For ongoing order updates or questions, continue using the same email.
  • Remember, we're here to help! Feel free to contact us for any queries or further assistance.

Quick Inquiry

 Note: Kindly utilize formal channels such as professional, corporate, academic emails, etc., for inquiries. The use of personal email for inquiries is not advised.